CN118178446A - 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 - Google Patents

三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 Download PDF

Info

Publication number
CN118178446A
CN118178446A CN202410227642.9A CN202410227642A CN118178446A CN 118178446 A CN118178446 A CN 118178446A CN 202410227642 A CN202410227642 A CN 202410227642A CN 118178446 A CN118178446 A CN 118178446A
Authority
CN
China
Prior art keywords
fatty liver
liver
triacetyl
alcoholic fatty
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410227642.9A
Other languages
English (en)
Chinese (zh)
Inventor
朱海波
史会杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Gushen Life Health Technology Co ltd
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Beijing Gushen Life Health Technology Co ltd
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Gushen Life Health Technology Co ltd, Institute of Materia Medica of CAMS and PUMC filed Critical Beijing Gushen Life Health Technology Co ltd
Publication of CN118178446A publication Critical patent/CN118178446A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202410227642.9A 2015-12-31 2016-12-31 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 Pending CN118178446A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015110341990 2015-12-31
CN201511034199 2015-12-31
CN201611266703.4A CN106943420A (zh) 2015-12-31 2016-12-31 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201611266703.4A Division CN106943420A (zh) 2015-12-31 2016-12-31 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (1)

Publication Number Publication Date
CN118178446A true CN118178446A (zh) 2024-06-14

Family

ID=59224622

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410227642.9A Pending CN118178446A (zh) 2015-12-31 2016-12-31 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
CN201611266703.4A Pending CN106943420A (zh) 2015-12-31 2016-12-31 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611266703.4A Pending CN106943420A (zh) 2015-12-31 2016-12-31 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Country Status (11)

Country Link
US (1) US11058703B2 (https=)
EP (1) EP3398604A4 (https=)
JP (1) JP7382716B2 (https=)
KR (1) KR102676056B1 (https=)
CN (2) CN118178446A (https=)
AU (1) AU2016383376B2 (https=)
CA (1) CA3010097C (https=)
HK (1) HK1255689A1 (https=)
RU (1) RU2759916C2 (https=)
WO (1) WO2017114413A1 (https=)
ZA (1) ZA201805080B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103336A1 (zh) * 2023-11-15 2025-05-22 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
CN100427534C (zh) * 2004-03-19 2008-10-22 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
JP5688229B2 (ja) 2010-03-19 2015-03-25 国立大学法人名古屋大学 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
CN102125580A (zh) 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
AU2012245996B2 (en) * 2011-04-22 2016-09-01 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
AU2013204500A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
CN104211747B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 5’-磷酸-n6-（3-羟基苯基）腺苷的制备及医药用途
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) * 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103336A1 (zh) * 2023-11-15 2025-05-22 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Also Published As

Publication number Publication date
KR20180100152A (ko) 2018-09-07
CN106943420A (zh) 2017-07-14
KR102676056B1 (ko) 2024-06-19
HK1255689A1 (en) 2019-08-23
JP7382716B2 (ja) 2023-11-17
CA3010097A1 (en) 2017-07-06
AU2016383376B2 (en) 2022-07-28
US11058703B2 (en) 2021-07-13
EP3398604A1 (en) 2018-11-07
RU2018126158A (ru) 2020-01-31
WO2017114413A1 (zh) 2017-07-06
ZA201805080B (en) 2019-10-30
CA3010097C (en) 2023-08-22
RU2759916C2 (ru) 2021-11-18
US20190022120A1 (en) 2019-01-24
JP2019500379A (ja) 2019-01-10
RU2018126158A3 (https=) 2020-03-11
EP3398604A4 (en) 2019-06-19
AU2016383376A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
CN118178446A (zh) 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
RU2697670C9 (ru) Фармацевтическая композиция, содержащая силибин и экстракт корня пуэрарии
JP2023145714A (ja) 脂肪肝の予防または処置用医薬組成物
US10959963B2 (en) Method for the treatment of fatty liver disease
CN111759853B (zh) 一种药物组合物及其用途
CN110946986A (zh) 一种寡肽在制备防治非酒精性脂肪肝病药物中的应用
CN112370496A (zh) 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用
CN112933120B (zh) 贝壳杉提取物在制备抗非酒精性脂肪肝的产品中的应用
CN117653650A (zh) 三乙酰基-3-羟基苯基腺苷在治疗肥胖症中的应用
CN117599076A (zh) 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用
CN109985072A (zh) 榆黄蘑提取物在制备治疗脂肪肝的药物、保健品、食品中的应用
CN115607546A (zh) Isarubrolone C、包含Isarubrolone C的药物组合物及应用
CN102657667A (zh) 二苯乙烯苷抑制肿瘤血管生成的新作用及其应用
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
CN110833550B (zh) 吡唑并嘧啶衍生物在治疗急性胰腺炎致肝损伤的用途
CN120983451A (zh) 柯里拉京在制备预防或治疗代谢相关脂肪性肝病产品中的应用
CN119367510A (zh) 一种多肽类激素在制备治疗非酒精性脂肪肝的药物中的用途
KR20260033973A (ko) 오에노테인 b를 포함하는 대사이상 간 질환의 예방 또는 치료용 조성물
CN119185287A (zh) 杜鹃素在制备治疗非酒精性脂肪肝药物中的用途
CN121846205A (zh) 一种用于预防和治疗代谢功能障碍相关脂肪性肝病的中药组合物、制备方法及其应用
CN119606963A (zh) 一种有效清除衰老肠细胞的药物及其在治疗肠道炎症病症中的应用
CN111632060A (zh) 一种含黄芩苷和二甲双胍的组合物及其制备方法与应用
HK1216614B (zh) 治疗脂肪肝疾病的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination